GlassScriptPhysician profile
Stephen Daniel Myers
NPI 1669444907
$470.53
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.42 · 2022: $43.90 · 2023: $366 · 2024: $41.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $324 · Education: $83.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $324.01 |
| Education | $83.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $79.33 | 2023 | Krazati |
| Novartis Pharmaceuticals Corporation | $67.10 | 2023 | Kisqali |
| Seagen INC. | $44.91 | 2022-2023 | Adcetris |
| Daiichi Sankyo INC. | $43.08 | 2022-2023 | Injectafer |
| Exelixis INC. | $41.20 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $41.04 | 2023 | Enhertu |
| Celgene Corporation | $38.06 | 2023 | Pomalyst |
| Janssen Biotech, INC. | $21.75 | 2023 | Tecvayli |
| Genentech USA, INC. | $21.66 | 2023 | Rozlytrek, Alecensa, Gavreto |
| Acrotech Biopharma INC. | $20.89 | 2023 | Beleodaq |
| Merck Sharp & Dohme LLC | $19.42 | 2019 | |
| Lilly USA, LLC | $16.64 | 2023 | Retevmo, Jaypirca, Verzenio |
| Pharmacosmos Therapeutics INC. | $15.45 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.